PI3K/Akt/mTOR Compound Library | PI3K/Akt/mTOR 化合物库 | MedChemExpress (MCE)

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials. MCE owns a unique collection of 575 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.更多产品详情查看：www.medchemexpress.cn/screening/PI3K/Akt/mTOR_Compound_Library.html

PI3K/Akt/mTOR Compound Library | PI3K/Akt/mTOR 化合物库 | MedChemExpress (MCE)信息由MedChemExpress (MCE)为您提供，如您想了解更多关于PI3K/Akt/mTOR Compound Library | PI3K/Akt/mTOR 化合物库 | MedChemExpress (MCE)报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途